**Patient Population**

See Section 3.0 for Complete Eligibility Details

- Female patients presenting with initial diagnosis of any type of cancer, including patients with DCIS
- Must not have initiated chemotherapy, radiation therapy, or endocrine therapy prior to registration
- Must not have had a prior hysterectomy, bilateral oophorectomy or sterilization of any method
- Must be pre-menopausal within the reproductive age range of 15-55 years
  
  ◊ Pre-menopausal will be defined as females meeting the following criteria: 1) Not currently on hormonal contraception with the presence of menses in the past 6 months 2) if no menstruation in the past 6 months, without hormonal manipulation, then confirmed FSH < 23 mIU/mL 3) If age < 47 years and on hormonal contraception then patient will be eligible regardless of menstrual history 4) If age ≥ 47 years and on hormonal contraception then FSH confirmed < 23 mIU/mL
- Pregnant females are eligible to participate in this study
- Patients must have the cognitive ability to participate in the study

**Treatment Plan**

See Section 5.0 for Complete Methodology Details

**Randomization:** Participating sites will be randomized to standard practice (Arm A) or intervention (Arm B). The unit of randomization will be the institution rather than the individual patient. Upon registration to this study, patients will be assigned to a study arm depending on the institutional assignment. Training for those randomized to Arm B will be offered at ECOG-ACRIN Group meetings and/or through a webinar on the ECOG website

**Study Arms and Intervention:**

- **Arm A: Non-Intervention** - Sites randomized to non-intervention will function with usual standard practice related to reproductive health
- **Arm B: Intervention** - Sites randomized to the intervention will receive training and intervention materials. Information specific to the intervention can be found in Addendum 1

Patients will be followed over time and all surveys will be administered as described per protocol

- See protocol for the Provider Assessment schedule and the Patient Reported Outcomes Assessment schedule
- Reproductive Health Related Endocrine Disruption in Cancer Care will be conducted on the first 200 patients who agree to participate (blood drawn)
- The Sexual Function Survey will be administered to all patients recruited

Patients will participate on this study for 24 months from registration

**Patient Enrollment**

All Sites: Oncology Patient Enrollment Network (OPEN) [https://open.ctsu.org](https://open.ctsu.org)

**Protocol Information**

ECOG-ACRIN Operations-Boston: 857-504-2900, [http://ecog-acrin.org](http://ecog-acrin.org) (Member Login)

Please Enroll Your Eligible Patients!
E1Q11 Available Through ECOG-ACRIN Cancer Research Group

EROS: Engendering Reproductive Health within Oncologic Survivorship

Schema

Selected and invited institutions

<table>
<thead>
<tr>
<th>Randomize Institution</th>
<th>Patient Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm A</td>
<td>Non-Intervention</td>
</tr>
<tr>
<td></td>
<td>Standard Practice</td>
</tr>
<tr>
<td>Arm B</td>
<td>Intervention</td>
</tr>
<tr>
<td></td>
<td>Training Modules Algorithm, Referral Development</td>
</tr>
<tr>
<td></td>
<td>Assessments</td>
</tr>
<tr>
<td></td>
<td>- Clinician Forms</td>
</tr>
<tr>
<td></td>
<td>- Patient Forms (Without RHA Form)</td>
</tr>
<tr>
<td>Arm A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Clinician Forms</td>
</tr>
<tr>
<td></td>
<td>- Patient Forms (With RHA Form)</td>
</tr>
</tbody>
</table>

Total Accrual Goal: 668